<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-142402</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">First Series of Patients With XDR and Pre-XDR TB Treated With Regimens That Included Meropenen-clavulanate in Argentina</dc:title>
<dc:description xml:lang="en">XDR (extensively drug-resistant) and pre-XDR tuberculosis (TB) seriously compromise prognosis and treatment possibilities, and inevitably require the use of group V drugs (World Health Organization). The progress of all patients with XDR and pre-XDR TB seen in a specialized unit during 2012 and 2013 and treated with regimens that included at least 6 months of meropenem-clavulanate (MPC), capreomycin, moxifloxacin, linezolid, clofazimine, high-dose isoniazid, PAS, and bedaquiline in 1 case, were retrospectively analyzed. Ten patients were treated, 9 with an extensive pattern of resistance to at least 6 drugs, and 1 because of adverse reactions and drug interactions leading to a similar situation. Eight of the 10 patients treated achieved bacteriological sputum conversion (2 consecutive negative monthly cultures) over a period of 2&#150;7 months, while 2 died. No adverse reactions attributable to prolonged administration of MPC were observed (AU)</dc:description>
<dc:creator>Cufré, Mónica</dc:creator>
<dc:creator>García, Ana</dc:creator>
<dc:creator>Vescovo, Marisa</dc:creator>
<dc:creator>González Montaner, Pablo</dc:creator>
<dc:creator>Palmero, Domingo</dc:creator>
<dc:creator>Poggi, Susana</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La tuberculosis extensamente resistente (TB-XDR) y pre-XDR comprometen seriamente el pronóstico de la enfermedad, y su tratamiento requiere inevitablemente el uso de fármacos del grupo V (Organización Mundial de la Salud [OMS]). Se analizó retrospectivamente la evolución de todos los pacientes con TB pre-XDR y XDR asistidos en un servicio especializado durante 2012 y 2013, medicados con regímenes que incluyeron por lo menos 6 meses de meropenem-clavulanato (MPC), capreomicina, moxifloxacina, linezolid, clofazimina, isoniacida en alta dosis, PAS y en un caso bedaquilina. Fueron tratados 10 pacientes, 9 de ellos con un extenso patrón de resistencia a un mínimo de 6 fármacos y uno por reacciones adversas e interacciones medicamentosas que generaron una situación análoga. Ocho de los 10 pacientes tratados, hicieron la conversión bacteriológica del esputo (2 cultivos mensuales consecutivos negativos) en un lapso de 2 a 7 meses, en tanto que 2 fallecieron. No se observaron reacciones adversas atribuibles a la administración prolongada del MPC (AU)</dc:description>
<dc:source>Arch Bronconeumol;51(10): e49-e52, oct. 2015. tab</dc:source>
<dc:identifier>ibc-142402</dc:identifier>
<dc:title xml:lang="es">Primera serie de pacientes con TB-XDR y pre-XDR tratados con esquemas que incluyeron meropenem-clavulanato en Argentina</dc:title>
<dc:subject>^d14778^s22057</dc:subject>
<dc:subject>^d914^s22073</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d914^s22044</dc:subject>
<dc:subject>^d22164^s22031</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d999^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7705^s22073</dc:subject>
<dc:subject>^d30997^s22012</dc:subject>
<dc:subject>^d30997^s22057</dc:subject>
<dc:subject>^d30997^s22016</dc:subject>
<dc:subject>^d2240^s22073</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201510</dc:date>
</metadata>
</record>
</ibecs-document>
